Bayer still plans to launch stroke drug asundexian in every country possible including Germany, despite a pricing-bill fight; Goldman Sachs projects $3.5B in peak sales.
Bayer said Tuesday it still plans to launch its new stroke drug in “every country possible,” including its home country of Germany, in spite of …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient…
In einer neuen Schlaganfall-Studie überzeugt Bayer mit einem Mittel, das dem Konzern vor zwei Jahren einen empfindlichen…
Germany's Bundestag passes a bill hiking drugmakers' patented-drug discount to 15.5%, aiming to cut €16.3B from 2027 health…
Following much opposition from drugmakers, Germany has scrapped its plan to install a program that would have reduced the price…
Backlash is brewing against a sweeping overhaul of Germany’s health insurance system as Eli Lilly and Boehringer Ingelheim slash…
